Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 1/20 | 0.37 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.36 |
| ▸ | ITGB1 | P05556 | 4/20 | 0.36 |
| ▸ | ITGAV | P06756 | 4/20 | 0.36 |
| ▸ | ITGA5 | P08648 | 4/20 | 0.36 |
| ▸ | GRN | P28799 | 2/20 | 0.36 |
| ▸ | SORT1 | Q99523 | 2/20 | 0.36 |
| ▸ | KIFC1 | Q9BW19 | 1/20 | 0.35 |
| ▸ | GPR34 | Q9UPC5 | 2/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | MME | P08473 | 1/20 | 0.35 |
| ▸ | ACE | P12821 | 1/20 | 0.35 |
| ▸ | CPA1 | P15085 | 1/20 | 0.35 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.35 |
| ▸ | CTSL | P07711 | 1/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.34 |
| ▸ | CASP3 | P42574 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23461787 | 0.89 | CXCR2 (0.49) | CXCR2GRNSORT1KIFC1PTPN1 | |
| SCHEMBL38666243 | 0.89 | CXCR2 (0.49) | CXCR2GRNSORT1KIFC1PTPN1 | |
| SCHEMBL23461785 | 0.89 | CXCR2 (0.49) | CXCR2GRNSORT1KIFC1PTPN1 | |
| SCHEMBL25549059 | 0.89 | CXCR2 (0.48) | CXCR2GRNSORT1KIFC1PTPN1 | |
| SCHEMBL25548714 | 0.88 | CXCR2 (0.38) | CXCR2ITGB3ITGB1ITGAVITGA5 | |
| SCHEMBL25549762 | 0.88 | CXCR2 (0.38) | CXCR2ITGB3ITGB1ITGAVITGA5 | |
| SCHEMBL23460807 | 0.86 | CXCR2 (0.43) | CXCR2ITGB3ITGB1ITGAVITGA5 | |
| SCHEMBL23460805 | 0.86 | CXCR2 (0.43) | CXCR2ITGB3ITGB1ITGAVITGA5 | |
| SCHEMBL38147098 | 0.86 | CXCR2 (0.43) | CXCR2ITGB3ITGB1ITGAVITGA5 | |
| SCHEMBL38662642 | 0.86 | GRN (0.40) | CXCR2ITGB3ITGB1ITGAVITGA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159438-A1 | ARYLAMIDES AND METHODS OF USE THEREOF | GENZYME CORPORATION | 2023-05-25 | — | — | US | disclosed |
| US-20230159438-A1 | ARYLAMIDES AND METHODS OF USE THEREOF | GENZYME CORPORATION | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159438-A1 | ARYLAMIDES AND METHODS OF USE THEREOF | CFTR, AADAC, ARSA | CXCR2 1205/4885ITGB3 3195/4885ITGB1 4082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.